Therefore, other serum biomarkers for pancreatic cancer, such as SPan-1, CA50, CA242, Dupan-2, and CEA, are used clinically (40, 41) even although their sensitivities and specificities are insufficient, and false-positive rates are as high as 20%–30%. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.